Skip to main content

Table 1 Everolimus in the treatment of hemodialysis patients with metastatic renal cell carcinomas

From: Efficacy and safety of everolimus treatment in a hemodialysis patient with metastatic atypical bronchial carcinoid: case report and literature review

Authors/reference

Study description

No. of patients included

No. of prior regimen

Everolimus dosage

Best responses

Duration of response

Safety

Thiery-Vuillemin A et al. [9]

Case reports

2

1; 1

5 mg

NA

NA

Grade II asthenia, diarrhea and mucositis; grade III hyperglycemia

Syrios J et al. [10]

Case reports

2

1; 1

10 mg

SD; CR

4 mo; 40 mo

Well tolerated

Adytia V et al. [11]

Single institution experience

6

NA

10 mg; 1 dosage reduction to 5 mg

SD

Median duration of therapy 1.9 mo (0.4–17)

5 patients: well tolerated, 1 patient: pneumonitis

Czarnecka AM et al. [12]

Single institution experience

1

2

10 mg

PD

4 mo

Well tolerated

Omae K et al. [13]

Single institution experience

4

1

 

SD

Median duration of therapy 6.7 mo

Grade II rash, diarrhea, pneumonitis, and mucositis

  1. Abbreviations: NA Not available, SD Stable disease, PD Progression of disease, mo Months